Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis

Abstract

The article presents the follow-up of a patient with severe systemic juvenile idiopathic arthritis (JIA) resistant to glucocorticosteroids, to the first genetically engineered biologic drug (GEBD) tocilizumab, a monoclonal antibody to the interleukin (IL) 6 receptor. Switching to the second GEBD — a monoclonal antibody to IL1β canakinumab — provided a remission of the disease. The first injection of the drug fully arrested the systemic symptoms of the disease, and the fourth one — the articular syndrome. The presented clinical example shows that switching to GEBD with a different mechanism of action — a monoclonal antibody to IL1β canakinumab — is highly effective and induces a remission of the disease in patients with systemic JIA resistant to tocilizumab. There were no adverse events under pressure of canakinumab therapy.

Keywords

• дети
• системный ювенильный идиопатический артрит
• канакинумаб
• человеческое моноклональное антитело к интерлейкину 1β